Education
About Us
Working with TipRanks
Follow Us
Y-Mabs Therapeutics (YMAB)
NASDAQ:YMAB
YMAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.03 - $17.78
Previous CloseN/A
Volume43.26K
Average Volume (3M)362.96K
Market Cap
$193.53M
Enterprise Value$519.80M
Total Cash (Recent Filing)-$16.88M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
May 12, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding45,218,178
10 Day Avg. Volume330,580
30 Day Avg. Volume362,961
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.58
Price to Cash Flow (P/CF)-30.20
P/FCF Ratio0.00
Enterprise Value/Market Cap2.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.18
Enterprise Value/Ebitda-16.89
Forecast
1Y Price Target
$17.27Price Target Upside322.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Pipeline DevelopmentYMAB has identified the next cohort of potential high-value oncology targets for development of SADA PRIT and will provide additional information in the upcoming update.
Sales GrowthDANYELZA's 4Q24 sales represent a ~32% increase vs. 3Q24.
Bears Say
EarningsY-mAbs recorded a 4Q24 net loss of $0.15 per share compared to a previously forecasted net loss of $0.04 per share.
Revenue Guidance2025 total revenue guidance of $75-90M were below expectations and imply declining growth of -6% year-over-year at the mid-point.
---
Ownership Overview
24.00% Insiders
7.73% Mutual Funds
35.48% Other Institutional Investors
22.42% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
YMAB FAQ
What was Y-Mabs Therapeutics’s price range in the past 12 months?
Y-Mabs Therapeutics lowest stock price was $4.03 and its highest was $17.78 in the past 12 months.
What is Y-Mabs Therapeutics’s market cap?
Y-Mabs Therapeutics’s market cap is $193.53M.
When is Y-Mabs Therapeutics’s upcoming earnings report date?
Y-Mabs Therapeutics’s upcoming earnings report date is May 12, 2025 which is in 33 days.
How were Y-Mabs Therapeutics’s earnings last quarter?
Y-Mabs Therapeutics released its earnings results on Mar 04, 2025. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.116 by -$0.034.
Is Y-Mabs Therapeutics overvalued?
According to Wall Street analysts Y-Mabs Therapeutics’s price is currently Undervalued.
Does Y-Mabs Therapeutics pay dividends?
Y-Mabs Therapeutics does not currently pay dividends.
What is Y-Mabs Therapeutics’s EPS estimate?
Y-Mabs Therapeutics’s EPS estimate is -0.21.
How many shares outstanding does Y-Mabs Therapeutics have?
Y-Mabs Therapeutics has 45,218,178 shares outstanding.
What happened to Y-Mabs Therapeutics’s price movement after its last earnings report?
Y-Mabs Therapeutics reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.116. Following the earnings report the stock price went down -4.432%.
Which hedge fund is a major shareholder of Y-Mabs Therapeutics?
Currently, no hedge funds are holding shares in YMAB
---
Y-Mabs Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.27 (322.25% Upside)
$17.27 (322.25% Upside)
Blogger Sentiment
Bearish
YMAB Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 17.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $76.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.69%
12-Months-Change
Fundamentals
Return on Equity
-30.74%
Trailing 12-Months
Asset Growth
-6.23%
Trailing 12-Months
Company Description
Y-Mabs Therapeutics
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
---
YMAB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive achievements, particularly in international revenue growth, radiopharmaceutical platform progress, and strong financial positioning. However, these were balanced by challenges, including revenue decline in the U.S., increased net loss, and difficulties in patient enrollment for trials. The strategic realignment is expected to address some of these challenges.Read More>---
YMAB Stock 12 Month Forecast
Average Price Target
$17.27
▲(322.25% Upside)
Technical Analysis
Best Analysts Covering YMAB
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
-3.71%
reiterated a sell rating last month
Copying Michael Ulz's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of -3.71% per trade.
---